BRIEF

on MONOGRAM ORTHOPAEDICS INC (NASDAQ:MGRM)

Monogram Technologies Obtains Approval for Clinical Trials in India

Stock price chart of MONOGRAM ORTHOPAEDICS INC (EBR:MGRM) showing fluctuations.

Monogram Technologies Inc. has received regulatory approval from India's Central Drugs Standard Control Organization to conduct a clinical investigation of its mBôs TKA system. This trial, in collaboration with Shalby Hospitals, will involve 102 patients and evaluates the system's safety and effectiveness. Patient enrollment is expected to begin shortly, with surgeries anticipated within 90 business days.

The study marks a significant milestone in the advancement of Monogram's AI-driven robotics in orthopedic surgery. By proving their technology in real surgical settings, Monogram aims to build clinical confidence and progress towards commercial launch. The company will also deploy full-time employees in India to ensure proper training and trial execution.

Key figures, including Dr. Vikram I. Shah, have expressed optimism about the trial's impact on orthopedic care innovation, positioning India as a leader in global medical advancements.

R. P.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all MONOGRAM ORTHOPAEDICS INC news